The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Tools for Myositis Diagnosis, Classification & Management

New Tools for Myositis Diagnosis, Classification & Management

April 15, 2019 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Anti-NT5C1a in IBM

Early immunohistochemical studies suggested qB cells are sparse in the muscles of IBM patients.35 However, more recent evidence shows that in gene expression profiling, immunoglobulin transcripts are abundant in their muscles, including the antibody-producing CD138+ plasma cells.36

You Might Also Like
  • Tips for Myositis Management
  • Myositis AutoantibodiesTriggered by Statins
  • Myositis Autoantibodies as Biomarkers
Explore This Issue
April 2019
Also By This Author
  • Road Rules for Social Media: As More Rheumatologists Go Online to Tweet, Chat or Post, They Must Learn How to Tread Wisely

“Where there are plasma cells and immunoglobulin transcripts, you expect to find an autoantibody,” said Dr. Mammen. Researchers identified an autoantibody, cytosolic 5’ nucleotidase 1A (NT5C1a), in patients with IBM. “This protein is abundant in skeletal muscle—it catalyzes nucleotide hydrolysis to nucleosides—but its function in muscle is not well understood.” Anti-NT5C1a is localized within rimmed vacuoles or around perinuclear areas of the IBM muscle.37 Patients with IBM who have NT5C1a antibodies tend to have more severe disease.38

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Mammen proposed a speculative model of IBM pathogenesis based on genetic susceptibility toward autophagy and a strong autoimmune component.

“Maybe some patients with IBM have this genetic susceptibility to a myodegenerative process. Maybe this FYCO1 variant makes them less able to handle misfolded proteins. As the patients age, they have abnormal protein accumulation that causes damage to the muscle and cellular stress, which causes more abnormal protein accumulation,” he said. “Then, I could imagine that the damage to the muscle in patients who have the right immunogenetic predisposition—they’re male, maybe they have the right environmental triggers—these things come together and cause the initiation of autoimmunity.” Autoreactive T cells and autoantibodies come back to do more muscle damage, he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There are no approved treatments for IBM and most clinicians don’t believe immunosuppression has a significant sustained effect, so resist the urge to use immunosuppressants in these patients, said Dr. Mammen. “We need to develop drugs to deplete aggressive CD57+ and cytotoxic T cells.”

Exercise, such as low-impact aerobics, stretching and endurance exercises,
and physical therapy are helpful recom­mendations for these patients, he concluded. He recommended foot to ankle orthotics for patients with foot drop and training family members in the Heimlich maneuver to intervene when patients experience dysphagia.


Susan Bernstein is a freelance journalist based in Atlanta.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271–2282.
  2. Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October, 2016. Neuromuscul Disord. 2018 Jan;28(1):87–89.
  3. Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016 Sep;23(5):218–226.
  4. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975 Feb 13;292(7):344–347.
  5. Alexanderson H, Broman L, Tollback A, et al. Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2006 Feb 15;55(1):114–122.
  6. Trallero-Araguas E, Grau-Junyent JM, Labirua-Iturburu A, et al. Clinical manifestations and long-term outcome of anti-Jo-1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016 Oct;46(2):225–231.
  7. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009 Jun;48(6):607–612.
  8. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001 Nov;40(11):1262–1273.
  9. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine (Baltimore). 2005 Jul;84(4):231–249.
  10. Aguila LA, Lopes MR, Pretti FZ, et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol. 2014 Aug;33(8):1093–1098.
  11. Medsger Jr. TA, Rodnan GP, Moossy J, et al. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1968 Aug;11(4):554–568.
  12. Thompson JM, Bluestone R, Bywaters EGL, et al. Skeletal muscle involvement in systemic sclerosis. Ann Rheum Dis. 1969 May;28(3):281–288.
  13. Jung M, Bonner A, Hudson M, et al. Myopathy is a poor prognostic feature in systemic sclerosis: Results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand J Rheumatol. 2014 Mar;43(3):217–220.
  14. Paik JJ, Wigley FM, Mejia AF, et al. Independent association of severity of muscle weakness with disability as Measured by the Health Assessment Questionnaire Disability Index in scleroderma. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1695–1703.
  15. Paik JJ, Wigley FM, Lloyd TE, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1416–1425.
  16. Paik JJ, Wigley FM, Shah AA, et al. Association of fibrosing myopathy in systemic sclerosis and higher mortality. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1764–1770.
  17. Corallo C, Cutolo M, Volpi N, et al. Histopathological findings in systemic sclerosis-related myopathy: Fibrosis and microangiopathy with lack of cellular inflammation. Ther Adv Musculoskelet Dis. 2017 Jan;9(1):3–10.
  18. Halla JT, Koopman WJ, Fallahi S, et al. Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum. 1984 Jul;27(7):737–743.
  19. Meyer A, Lefevre G, Bierry G, et al. In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: An overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine (Baltimore). 2015 May;94(20):e523.
  20. Gonzalez-Gay MA, Montecucco C, Selva-O’Callaghan A, et al. Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. Clin Exp Rheumatol. 2018 Jan–Feb;36(1):44–49.
  21. Tsokos GC, Moutsopoulos HM, Steinberg AD. Muscle involvement in systemic lupus erythematosus. JAMA. 1981 Aug;246(7):766–768.
  22. Lim KL, Abdul-Wahab R, Lowe J, et al. Muscle biopsy abnormalities in systemic lupus erythematosus: Correlation with clinical and laboratory parameters. Ann Rheum Dis. 1994 Mar;53(3):178–182.
  23. De Lorenzo R, Pinal-Fernandez I, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology. 2018 Jun 5;90(23):e2068–e2076.
  24. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009 Apr;60(4):1112–1118.
  25. Rigolet A, Musset L, Dubourg O, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease. Medicine (Baltimore). 2012 Mar;91(2):95–102.
  26. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008 Feb 5;70(6):418–424.
  27. Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017 Jan 17;88(3):304–313.
  28. Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Dis. 2013 Dec;23(12):1044–1055.
  29. Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 Jul;83(5):426–433.
  30. Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017 Feb;81(2):227–239.
  31. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984 Aug;16(2):209–215.
  32. Fyhr I-M, Moslemi A-R, Lindberg C, et al. T cell receptor β-chain repertoire in inclusion body myositis. J Neuroimmunol. 1998 Nov;91(1–2):129–134.
  33. Müntzing K, Lindberg C, Moslemi A-R, et al. Inclusion body myositis: Clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol. 2003 Aug;58(2):195–200.
  34. Dimitri D, Benveniste O, Dubourg O, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain. 2006 Apr;129(Pt 4):986–995.
  35. Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016 May;139(Pt 5):1348–1360.
  36. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005 Dec;65(11):1782–1787.
  37. Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013 Mar;73(3):408–418.
  38. Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):373–378.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: 2018 ACR/ARHP Annual Meeting, fibrosing myopathy, idiopathic inflammatory myopathies, inclusion body myositis (IBM), overlap myositisIssue: April 2019

You Might Also Like:
  • Tips for Myositis Management
  • Myositis AutoantibodiesTriggered by Statins
  • Myositis Autoantibodies as Biomarkers
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)